On December 8, 2020, when most of America was consumed with what The Guardian called Donald Trump’s “desperate, mendacious, frenzied and sometimes farcical” attempt to remain president, the Senate’s Homeland Security and Governmental Affairs Committee held a hearing on the “Medical Response to Covid-19.” One of the witnesses, a pulmonologist named Dr. Pierre Kory, insisted he had great news.
“We have a solution to this crisis,” he said unequivocally.
“There is a drug that is proving to have a miraculous impact.”
Kory was referring to an FDA-approved medicine called ivermectin. A genuine wonder drug in other realms, ivermectin has all but eliminated parasitic diseases like river blindness and elephantiasis, helping discoverer Satoshi Ōmura win the Nobel Prize in 2015. As far as its uses in the pandemic went, however, research was still scant. Could it really be a magic Covid-19 bullet?
Kory had been trying to make such a case, but complained to the Senate that public efforts had been stifled, because “every time we mention ivermectin, we get put in Facebook jail.” A Catch-22 seemed to be ensnaring science. With the world desperate for news about an unprecedented disaster, Silicon Valley had essentially decided to disallow discussion of a potential solution — disallow calls for more research and more study — because not enough research and study had been done. Once, people weren’t allowed to take drugs before they got FDA approval. Now, they can’t talk about them.
by Matt Taibbi
Join: 👉 https://t.me/acnewspatriots
The opinions expressed by contributors and/or content partners are their own and do not necessarily reflect the views of AC.NEWS
Disclaimer: This article may contain statements that reflect the opinion of the author. The contents of this article are of sole responsibility of the author(s). AC.News will not be responsible for any inaccurate or incorrect statement in this article www.ac.news websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner. Reprinting this article: Non-commercial use OK. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.
Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.